{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifsrvuyhxktfiytxf4txcyesqtg3opzyea67jsv7lq5phojlugvqy",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mna7sefxgn32"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/06/01/asco-pancreatic-lung-cancer-drugs-china-growth-as-drug-developer/?utm_campaign=rss",
  "publishedAt": "2026-06-01T13:30:37.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months",
  "title": "STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more",
  "updatedAt": "2026-06-01T13:30:42.000Z"
}